Hsu PC - Search Results

1

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.

Lu CW, Pang JS, Ko YS, Chang CJ, Wang CW, Chen WT, Chen CB, Hui RC, Hung SI, Lu LY, Lu KL, Wang CL, Wu CE, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Chen MJ, Chung WH. Lu CW, et al. Among authors: hsu pc. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):328-339. doi: 10.1111/jdv.18703. Epub 2022 Nov 16. J Eur Acad Dermatol Venereol. 2023. PMID: 36366861

2

Overall response to first-line tyrosine kinase inhibitor and second-line chemotherapy is predictive of survival outcome in epidermal growth factor receptor-mutated adenocarcinoma.

Kuo SC, Hsu PC, Chen CH, Yu CT, Wang CL, Chung FT, Lin SM, Lo YL, Chen TC, Liu CY, Yang CT. Kuo SC, et al. Among authors: hsu pc. Chemotherapy. 2014;60(3):201-10. doi: 10.1159/000371735. Chemotherapy. 2014. PMID: 25871639

3

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.

Hsu PC, Chiu LC, Li SH, Chen CH, Wang CL, Kao KC, Chang JW, Wang CW, Yu CT, Chung FT, Yang CT, Liu CY. Hsu PC, et al. Biomed J. 2016 Apr;39(2):121-9. doi: 10.1016/j.bj.2015.07.002. Epub 2016 Jun 9. Biomed J. 2016. PMID: 27372167 Free PMC article.

4

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.

Li SH, Liu CY, Hsu PC, Fang YF, Wang CC, Kao KC, Tseng LC, Yang CT. Li SH, et al. Among authors: hsu pc. Expert Rev Anticancer Ther. 2018 Jan;18(1):81-89. doi: 10.1080/14737140.2018.1409623. Epub 2017 Dec 2. Expert Rev Anticancer Ther. 2018. PMID: 29172778

5

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.

Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. Liu CY, et al. Among authors: hsu pc. Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228636 Free PMC article.

6

Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis.

Hsu PC, Li SH, Yang CT. Hsu PC, et al. J Thorac Oncol. 2018 Nov;13(11):e227-e230. doi: 10.1016/j.jtho.2018.06.022. J Thorac Oncol. 2018. PMID: 30368415 Free article. No abstract available.

7

Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study.

Hsu PC, Chang JW, Wang CC, Wu CT, Lin YC, Wang CL, Lin TY, Li SH, Wu YC, Kuo SC, Yang CT, Liu CY, Chen CH. Hsu PC, et al. Thorac Cancer. 2019 Aug;10(8):1683-1691. doi: 10.1111/1759-7714.13125. Epub 2019 Jul 5. Thorac Cancer. 2019. PMID: 31276309 Free PMC article.

8

Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.

Chu CH, Chiu TH, Wang CC, Chang WC, Huang AC, Liu CY, Wang CL, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Chu CH, et al. Among authors: hsu pc. Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 Apr 13. Thorac Cancer. 2020. PMID: 32281272 Free PMC article.

9

Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.

Lu CW, Wang TY, Yen CF, Chen KH, Wu CE, Wang CL, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Lin YJ, Chen MJ, Chen CB, Su Pang JH, Chung WH, Ko YS. Lu CW, et al. Among authors: hsu pc. Int J Dermatol. 2021 Feb;60(2):179-184. doi: 10.1111/ijd.15099. Epub 2020 Sep 25. Int J Dermatol. 2021. PMID: 32975313

10

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study.

Hsu PC, Huang CY, Wang CC, Kuo SC, Chu CH, Tung PH, Huang AC, Wang CL, Chiu LC, Fang YF, Yang CT. Hsu PC, et al. Pharmaceuticals (Basel). 2020 Oct 23;13(11):331. doi: 10.3390/ph13110331. Pharmaceuticals (Basel). 2020. PMID: 33113888 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

635 results

Search Page